LADENBURG THALM/SH SH Forecasts Strong Price Appreciation for Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical (NASDAQ:DRTS) had its price objective hoisted by research analysts at LADENBURG THALM/SH SH from $12.00 to $14.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price target suggests a potential upside of 45.23% from the company’s previous close.

Other research analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Citigroup raised their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Piper Sandler reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. HC Wainwright raised their price objective on shares of Alpha Tau Medical from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Zacks Research raised shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.75.

Alpha Tau Medical Trading Down 2.4%

NASDAQ:DRTS opened at $9.64 on Tuesday. The company has a current ratio of 7.45, a quick ratio of 7.45 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $848.42 million, a price-to-earnings ratio of -18.19 and a beta of 1.11. The firm has a fifty day simple moving average of $7.51 and a two-hundred day simple moving average of $6.25. Alpha Tau Medical has a 12 month low of $2.78 and a 12 month high of $10.80.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Analysts expect that Alpha Tau Medical will post -0.5 EPS for the current fiscal year.

Institutional Trading of Alpha Tau Medical

Hedge funds have recently added to or reduced their stakes in the stock. Trifecta Capital Advisors LLC bought a new stake in Alpha Tau Medical in the fourth quarter worth about $48,000. Envestnet Asset Management Inc. bought a new stake in Alpha Tau Medical in the third quarter worth about $62,000. Principal Financial Group Inc. bought a new stake in Alpha Tau Medical in the first quarter worth about $132,000. Bank of America Corp DE raised its position in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after acquiring an additional 21,677 shares during the period. Finally, Wells Fargo & Company MN increased its stake in shares of Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after purchasing an additional 17,500 shares in the last quarter. Institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.